Muhammad Riedha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Muhammad Riedha has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Cora Burgwinkel
Epidemiology, Biostatistics and Prevention Institute (EBPI) and Center for Reproducible Science and Research Synthesis (CRS), University of Zurich
1 shared publication - Evelyne Decullier
Hospices Civils de Lyon, Pôle Santé Publique, Unité de Recherche Clinique, Lyon, France
1 shared publication - Giulia Varvarà
Univ Rennes, CHU Rennes, Inserm, Institut de recherche en santé, environnement et travail (Irset)-UMR_S 1085, Rennes, France
1 shared publication - Grigorius Papapostolou
Health Data Science Center, Berlin Institute of Health at Charite, Universitaetsmedizin Berlin, Berlin, Germany
1 shared publication - Han Chang Chiam
Center for Medical Data Science Medical University of Vienna Vienna Austria
1 shared publication - Jifan Wang
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 27 August 2026
- Published by Elsevier in SSRN Electronic Journal
Perspectives of Stakeholders on Clinical Trial Data Sharing: A Scoping Review
Background: Clinical Trial Data Sharing (CTDS) for secondary use could improve research transparency and reproducibility. However, privacy matters, unharmonized data, and inadequate academic incentives and infrastructure hinder its broad adoption. This study maps the varied perspectives of clinical trial stakeholders, including patients, researchers, and institutional actors, to characterize existing governing frameworks and formulate implementable recommendations for equitable data sharing.Methods: This scoping review followed the Joanna Briggs Institute (JBI) methodology and was reported in accordance with PRISMA-ScR guidelines. Systematic searches were performed in three major databases, PubMed, EMBASE, and Web of Science (April 2025), followed by manual citation tracking (through February 2026). Inclusion criteria focused on English-language articles published between 2019 and 2025 that addressed stakeholder perspectives on the secondary use of clinical trial data. Eligibility screening was carried out using a Population-Concept-Context framework in Covidence, and data were analysed using inductive content analysis.Results: Of 4,615 records identified, 43 articles met inclusion criteria, concentrated in Europe and the Americas (68%). Africa and the Western Pacific contributed moderately, while South-East Asia and the Eastern Mediterranean were scarce. Patients were the most-studied stakeholder (n=23); funder perspectives were absent. Seven cross-cutting themes emerged: privacy, altruism, scientific progress, consent, oversight, trust, and secure infrastructure. Data protection concerns, administrative burden, and fear of being scooped were prominent barriers, whereas altruism and journal/funder mandates were key motivators. A lack of regulatory literacy was prevalent among all stakeholder groups. Further, there is much disagreement around consent models. Broad consent is operationally preferred, but data professionals are skeptical of its ethical transparency.Discussion: Operationalizing CTDS requires a systemic shift beyond one-size-fits-all technical solutions. We propose eight concrete recommendations to achieve this goal: (1) implement mandatory data sharing literacy training; (2) modernize broad consent as the default preference; (3) reform academic incentives; (4) institute independent multi-stakeholder governance; (5) enable community co-design; (6) expand research among underrepresented stakeholder groups; (7) invest in shared repository infrastructure; and (8) establish transparent benefit-sharing mechanisms. Addressing the near-total absence of technical-professional and funder standpoints is a priority. A trustworthy and equitable CTDS ecosystem will require synchronized reform across infrastructure, policy, and institutional culture.
- 27 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPerspectives of Stakeholders on Clinical Trial Data Sharing: A Scoping Review
Background: Clinical Trial Data Sharing (CTDS) for secondary use could improve research transparency and reproducibility. However, privacy matters, unharmonized data, and inadequate academic incentives and infrastructure hinder its broad adoption. This study maps the varied perspectives of clinical trial stakeholders, including patients, researchers, and institutional actors, to characterize existing governing frameworks and formulate implementable recommendations for equitable data sharing.Methods: This scoping review followed the Joanna Briggs Institute (JBI) methodology and was reported in accordance with PRISMA-ScR guidelines. Systematic searches were performed in three major databases, PubMed, EMBASE, and Web of Science (April 2025), followed by manual citation tracking (through February 2026). Inclusion criteria focused on English-language articles published between 2019 and 2025 that addressed stakeholder perspectives on the secondary use of clinical trial data. Eligibility screening was carried out using a Population-Concept-Context framework in Covidence, and data were analysed using inductive content analysis.Results: Of 4,615 records identified, 43 articles met inclusion criteria, concentrated in Europe and the Americas (68%). Africa and the Western Pacific contributed moderately, while South-East Asia and the Eastern Mediterranean were scarce. Patients were the most-studied stakeholder (n=23); funder perspectives were absent. Seven cross-cutting themes emerged: privacy, altruism, scientific progress, consent, oversight, trust, and secure infrastructure. Data protection concerns, administrative burden, and fear of being scooped were prominent barriers, whereas altruism and journal/funder mandates were key motivators. A lack of regulatory literacy was prevalent among all stakeholder groups. Further, there is much disagreement around consent models. Broad consent is operationally preferred, but data professionals are skeptical of its ethical transparency.Discussion: Operationalizing CTDS requires a systemic shift beyond one-size-fits-all technical solutions. We propose eight concrete recommendations to achieve this goal: (1) implement mandatory data sharing literacy training; (2) modernize broad consent as the default preference; (3) reform academic incentives; (4) institute independent multi-stakeholder governance; (5) enable community co-design; (6) expand research among underrepresented stakeholder groups; (7) invest in shared repository infrastructure; and (8) establish transparent benefit-sharing mechanisms. Addressing the near-total absence of technical-professional and funder standpoints is a priority. A trustworthy and equitable CTDS ecosystem will require synchronized reform across infrastructure, policy, and institutional culture.
- Open Access
Supporting Reanalysis and Reuse of Clinical Trial Data: A Case Study
Background: Reproducing published findings from clinical trials is a critical component of scientific transparency, yet it remains a challenging and under-practiced task. Despite increasing emphasis on reproducibility and data reuse in research policies, few real-world examples exist where independent teams have reproduced complex analyses using clinical trial data. In this case study, the aim was to independently reproduce the key findings of a high-impact clinical trial on rectal cancer treatment using shared trial data. Method: We organized a multi-team datathon, where each team was provided with the same dataset and supporting material, and was tasked to reproduce the results of the CAO/ARO/AIO-04 trial, with optional additional analysis. We contacted the original investigators for data access and reuse, and consulted them to understand the study, clinically and scientifically. Results: Five teams used R or Python to reproduce the statistical results, and the corresponding scripts can be found on Gitlab. All teams reproduced the analyses for primary outcome disease-free survival (DFS). The key findings on DFS were consistently reproduced, reinforcing confidence in the trial main conclusions. Result robustness was investigated using a different analytical software or statistical models. Nevertheless, challenges were encountered when the supplementary materials were not easily identified. Minor reporting issues were noticed in the reproduced paper. Conclusion: Reproduction of a major oncology clinical trial confirmed the reliability of its main conclusions. Divergences highlighted reporting gaps, such as incomplete protocols and broken links, that future trials should address. This case study demonstrates the value of systematic reproducibility checks for clinical research transparency and challenges in data sharing for reproducibility.
Open AccessSupporting Reanalysis and Reuse of Clinical Trial Data: A Case Study
Background: Reproducing published findings from clinical trials is a critical component of scientific transparency, yet it remains a challenging and under-practiced task. Despite increasing emphasis on reproducibility and data reuse in research policies, few real-world examples exist where independent teams have reproduced complex analyses using clinical trial data. In this case study, the aim was to independently reproduce the key findings of a high-impact clinical trial on rectal cancer treatment using shared trial data. Method: We organized a multi-team datathon, where each team was provided with the same dataset and supporting material, and was tasked to reproduce the results of the CAO/ARO/AIO-04 trial, with optional additional analysis. We contacted the original investigators for data access and reuse, and consulted them to understand the study, clinically and scientifically. Results: Five teams used R or Python to reproduce the statistical results, and the corresponding scripts can be found on Gitlab. All teams reproduced the analyses for primary outcome disease-free survival (DFS). The key findings on DFS were consistently reproduced, reinforcing confidence in the trial main conclusions. Result robustness was investigated using a different analytical software or statistical models. Nevertheless, challenges were encountered when the supplementary materials were not easily identified. Minor reporting issues were noticed in the reproduced paper. Conclusion: Reproduction of a major oncology clinical trial confirmed the reliability of its main conclusions. Divergences highlighted reporting gaps, such as incomplete protocols and broken links, that future trials should address. This case study demonstrates the value of systematic reproducibility checks for clinical research transparency and challenges in data sharing for reproducibility.